Depletion of L-asparagine supply and apoptosis of leukemia cells induced by human glycosylasparaginase

Leukemia

Volumn 23, Issue 6, 2009, Pages 1167-1171

  Kelo, E ^a,b   Noronkoski, T ^c   Mononen, Ilkka ^d,e  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b Oy Reagena Ltd   (Finland)

^c KYMENLAAKSO CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARAGINE; N4 (BETA N ACETYLGLUCOSAMINYL)ASPARAGINASE;

APOPTOSIS; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME THERAPY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEPLETION;

EID: 67349105630     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.387     Document Type: Article

References (12)

1. Ueno T, Ohtawa K, Mitsui K, Kodera Y, Hiroto M, Matsushima A et al Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia 1997; 11: 1858-1861.
2. Ollenschläger G, Roth E, Linkesch W, Jansen S, Simmel A, Mödder B. Asparaginase-induced derangements of glutamine metabolism: The pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 1988; 18: 512-516.
3. Kaartinen V, Mononen T, Laatikainen R, Mononen I. Substrate specificity and reaction mechanism of human glycosylasparaginase. The N glycosidic linkage of various glycoasparagines is cleaved through a reaction mechanism similar to L-asparaginase. J Biol Chem 1992; 267: 6855-6858.
4. Mononen I, Heisterkamp N, Dunder U, Romppanen EL, Noronkoski T, Kuronen I et al. Recombinant glycosylasparaginase and in vitro correction of aspartylglycosaminuria. FASEB J 1995; 9: 428-433.
5. Dunder U, Kaartinen V, Valtonen P, Väan̈änen E, Kosma V-M, Heisterkamp N et al. Enzyme replacement therapy in a mouse model of aspartylglucosaminuria. FASEB J 2000; 14: 361-367.
6. Noronkoski T, Stoineva I, Petkov D, Mononen I. Recombinant human glycosylasparaginase catalyzes hydrolysis of L-asparagine. FEBS Lett 1997; 412: 149-152.
7. Noronkoski T, Stoineva I, Ivanov I, Petkov D, Mononen I. Glycosylasparaginase-catalyzed synthesis and hydrolysis of β-aspartyl peptides. J Biol Chem 1998; 273: 26295-26297.
8. Kelo E, Noronkoski T, Stoineva I, Petkov D, Mononen I. Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi. FEBS Lett 2002; 528: 130-132.
9. Ramakers-van Woerden N, Beverloo H, Veerman A, Camitta B, Loonen A, van Wering E et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004; 18: 521-529.
10. Estlin E, Ronghe M, Burke G, Yule S. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 780-790.
11. Fine B, Kaspers G, Ho M, Loonen A, Boxer L. A genome-wide view of the in vitro response to L-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005; 65: 291-299.
12. Iwamoto S, Mihara K, Downing JR, Pui C-H, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007; 117: 1049-1057.